VMD Stock Analysis: Buy, Sell, or Hold?
VMD - Viemed Healthcare, Inc. Common Shares
$9.13
0.05 (0.55%)
▲
5d:
+2.47%
30d:
+1.67%
90d:
-24.73%
WAIT
LOW Confidence
Analysis Updated: Oct 2, 2026 12:00 AM ET
Earnings: Nov 04, 2026
Get Alerted When VMD Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 MIXED SIGNALS: VMD shows conflicting indicators. Wait for confirmation before entering.
📊 MIXED SIGNALS: VMD shows conflicting indicators. Wait for confirmation before entering.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$16.29
Based on 14.5% avg growth
INTRINSIC VALUE TODAY
$10.12
9.8% Margin of Safety
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 15.4x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: VMD is currently trading at $9.13, which is considered extended relative to its 30-day fair value range of $8.80 to $9.10. The stock's valuation (Forward PE: 16.7) is in line with its historical norms (15.4). At these levels, the market is pricing in 2.8% annual earnings growth.
Technical Outlook: Technically, VMD is in a downtrend. The price is approaching resistance at $9.24. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: The stock scores a mixed 47/100 on our bottoming-setup gauge, with only partial signs of a stabilized entry point. In the options market, Implied Volatility is low (0th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $12.50 (+37.7%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, VMD is in a downtrend. The price is approaching resistance at $9.24. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: The stock scores a mixed 47/100 on our bottoming-setup gauge, with only partial signs of a stabilized entry point. In the options market, Implied Volatility is low (0th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $12.50 (+37.7%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$8.80 -
$9.10
Company Quality Score
49/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
63.1%
All Signals
- BEARISH: Price extended above range
- BULLISH: Options cheap (IV 0th percentile)
- NEUTRAL: Mixed technical signals (47/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 37.7% below Wall St target ($12.50)
- BULLISH: Expecting earnings turnaround to 2.8% growth with 23.9% revenue growth
- WARNING: Composite score 49/100 in the bottom quintile — this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$8.80 -
$9.10
Current vs Trading Range
EXTENDED
Expected Move (7 Days)
±$0.76
(8.3%)
Support & Resistance Levels
Support Level
$8.66
Resistance Level
$9.24
Current Trend
Downtrend
Technical data as of
Oct 2, 2026
Fundamental Context
Forward P/E (Next Year Est.)
16.71
Wall Street Target
$12.50
(+37.7%)
Revenue Growth (YoY)
23.9%
Earnings Growth (YoY)
-12.4%
Profit Margin
4.8%
Valuation Premium vs History
+2.8% premium
PE vs Historical
16.7 vs 15.4
FAIR
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
+2.8%
(market-implied from PE analysis)
1-Year Target
$9.33
(+3%)
2-Year Target
$9.60
(+6%)
3-Year Target
$9.86
(+9%)
3-Yr Target (if PE normalizes)
(PE: 17→15)
PE COMPRESSION
$9.09
(+0%)
Earnings growth offset by PE compression
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 20.4, Growth: 31.5%)
$25.18
(+177%)
Base:
(SPY PE: 16.7, Growth: 31.5%)
$20.63
(+127%)
Bear:
(PE: 14.2, Growth: 31.5%)
$17.53
(+93%)
📈
Valuation based on Current Earnings
RECOVERY PLAY: Stock looks expensive now (25x PE), but valuation improves significantly next year (17x PE) as earnings recover.
Trailing PE: 25.28 | Current EPS (TTM): $0.36
Bull Case
$15.11
(+66%)
Analyst growth 50.9%, PE expands to 27.8
Base Case
$13.73
(+51%)
Market implied 50.9%, PE stable at 25.3
Bear Case
$6.19
(-32%)
Severe decline -20.0%, PE contracts to 21.5
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
Share & Embed Analysis
Last updated: October 02, 2026 4:20 PM ET
Data refreshes hourly during market hours. Next update: 5:20 PM
Data refreshes hourly during market hours. Next update: 5:20 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is VMD showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Medical Devices Stocks
Top-rated stocks in Medical Devices by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
BSX
Boston Scientific Corp |
STRONG BUY
34 analysts |
$61 | 62 BUY |
|
SYK
Stryker Corporation |
BUY
32 analysts |
$369 | 69 BUY |
|
DXCM
DexCom Inc |
STRONG BUY
27 analysts |
$94 | 47 HOLD |
|
MDT
Medtronic PLC |
BUY
32 analysts |
$105 | 64 BUY |
|
PODD
Insulet Corporation |
STRONG BUY
24 analysts |
$172 | 51 HOLD |
